

FINANCIAL STATEMENTS (Unaudited)
For the period from 01.07.2021 to 31.03.2022



The IBN SINA Pharmaceutical Industry Ltd.
Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,
Dhaka-1207, Bangladesh.

The IBN SINA Pharmaceutical Industry Ltd.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 31st March, 2022

	Notes	Amount in Taka	
		31 March 2022	30 June 2021
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04.A	2,320,873,685	2,209,734,247
Capital Work-In-Progress	05.1A	149,665,608	111,409,695
Right of Use Assets	05.2	89,930,973	9,566,112
Investment in Marketable Securities (AFS)	06	13,826,665	5,179,715
Investment in Associates	07	-	51,689,505
		2,574,296,932	2,387,579,274
Current Assets :			
Inventories	08.A	876,553,227	782,163,655
Trade and Other Receivables	09	33,986,808	27,271,285
Advances, Deposits & Prepayments	10.A	236,153,505	367,157,429
Cash & Cash Equivalents	11.A	371,691,320	281,235,883
		1,518,384,859	1,457,828,253
TOTAL ASSETS		<u>4,092,681,791</u>	<u>3,845,407,527</u>
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:			
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
Unrealised Gain on Marketable Securities (AFS)	14	168,300	145,087
Retained Earnings	15.A	2,096,879,661	1,829,226,006
Non Controlling Interest	15.B	20,781,500	3,351,582
		2,434,657,841	2,149,551,055
LIABILITIES:			
Non-Current Liabilities:			
Long Term Finance	16	392,160,992	419,621,065
Retirement Benefit Obligations	17.A	564,970	94,029
Lease Liability	17.B	84,563,410	1,993,508
Deferred Tax Liability	18	129,800,347	118,869,318
		607,089,719	540,577,920
Current Liabilities:			
Short Term Finance	20	444,905,388	377,502,715
Current Portion of Long Term Finance	21	65,448,342	67,532,217
Trade and Other Payable	22.A	407,432,076	430,947,383
Provision for Corporate Tax	23.A	133,148,425	279,296,238
		1,050,934,231	1,155,278,552
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		<u>4,092,681,791</u>	<u>3,845,407,527</u>
Net Assets Value (NAV) Per Share	31.A	77.26	68.69


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
April 21, 2022.



Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)
For the period from 1st July 2021 to 31st March, 2022

		Amount in Taka			
	Notes	July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021	January 01, 2022 to March 31, 2022	January 01, 2021 to March 31, 2021
REVENUE		6,407,260,968	5,399,371,735	1,879,425,116	1,791,871,586
Cost of goods sold	24	(3,737,968,554)	(3,148,664,470)	(1,077,550,732)	(1,028,463,176)
GROSS PROFIT		2,669,292,414	2,250,707,265	801,874,384	763,408,410
OPERATING EXPENSES		(2,052,542,721)	(1,728,887,613)	(671,381,883)	(626,405,804)
Administrative expenses	25.A	(152,971,642)	(136,508,808)	(47,851,682)	(47,960,598)
Selling & Distribution expenses	26	(1,899,571,079)	(1,592,378,805)	(623,530,201)	(578,445,206)
OPERATING PROFIT		616,749,693	521,819,652	130,492,501	137,002,606
Financial charges	34	(35,125,390)	(29,176,312)	(11,030,656)	(10,224,336)
Other income		17,214,009	8,213,662	1,856,563	1,942,926
Net profit from operation		598,838,312	500,857,001	121,318,408	128,721,195
Workers' P.P. fund & welfare fund	27	(28,655,331)	(24,205,503)	(5,826,792)	(6,129,580)
PROFIT BEFORE TAX		570,182,981	476,651,498	115,491,616	122,591,616
Income tax expenses:					
Current Tax	28.A	(155,754,362)	(135,321,891)	(28,897,463)	(35,608,344)
NET PROFIT AFTER TAX		414,428,619	341,329,607	86,594,153	86,983,271
PROFIT /(LOSS) ATTRIBUTABLE TO:					
Owners of the Company		414,498,701	341,329,607	86,616,035	86,983,271
Non-controlling interest		(70,082)	-	(21,882)	-
		<u>414,428,619</u>	<u>341,329,607</u>	<u>86,594,153</u>	<u>86,983,271</u>
Other Comprehensive Income:					
Change in fair value of marketable securities	29	25,792	442,395	(452,783)	69,800
Deferred tax		(2,579)	(44,240)	45,278	(6,980)
Total other comprehensive income for the period (net of tax)		23,213	398,156	(407,504)	62,820
Total Comprehensive Income for the period		414,451,832	341,727,762	86,186,649	87,046,091
Total Comprehensive income Attributable to:					
Owner of the Company		414,451,832	341,727,762	86,186,649	87,046,091
Non-controlling interest		(70,082)	-	(21,882)	-
		<u>414,381,750</u>	<u>341,727,762</u>	<u>86,208,531</u>	<u>87,046,091</u>
Earnings Per Share (EPS)	30.A	13.26	10.92	2.76	2.79
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
April 21, 2022.


Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the period from 1st July 2021 to 31st March, 2022

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (unrealized)	Retained Earnings	Non Controlling Interest	Total
Balance as at 1st July, 2020	312,436,270	4,392,110	(212,402)	1,460,390,581	40	1,777,006,599
Statement of profit or loss and other Comprehensive Income-2020-2021			357,489	489,123,389	(151,618)	489,329,260
Dividend for the year 30 June, 2020 (Cash-38.50%)				(120,287,964)		(120,287,964)
Issue during the year					3,503,160	3,503,160
Balance as at 30th June, 2021	312,436,270	4,392,110	145,087	1,829,226,006	3,351,582	2,149,551,055
Statement of profit or loss and other Comprehensive Income for period ended 31st March, 2022			23,213	414,498,701	(70,082)	414,451,832
Dividend for the year 30 June, 2021 (Cash-47%)				(146,845,047)		(146,845,047)
Issue during the year					17,500,000	17,500,000
Balance as at 31st March, 2022	312,436,270	4,392,110	168,300	2,096,879,660	20,781,500	2,434,657,841


CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the period from 1st July 2020 to 31st March, 2021

Amount in Taka


Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (unrealized)	Retained Earnings	Non Controlling Interest	Total
Balance as at 1st July, 2019	312,436,270	4,392,110	(126,137)	1,161,594,152		1,478,296,395
Statement of profit or loss and other Comprehensive Income-2019-2020			(86,265)	392,527,310		392,441,045
Dividend for the year 30 June, 2019 (Cash-30%)				(93,730,881)		(93,730,881)
Issue during the year					40	40
Balance as at 30th June, 2020	312,436,270	4,392,110	(212,402)	1,460,390,581	40	1,777,006,599
Statement of profit or loss and other Comprehensive Income for period ended 31st March, 2021			398,156	341,329,607		341,727,762
Dividend for the year 30 June, 2020 (Cash-38.50%)				(120,287,964)		(120,287,964)
Issue during the year					3,500,160	3,500,160
Balance as at 31st March, 2021	312,436,270	4,392,110	185,754	1,681,432,224	3,500,200	2,001,946,557


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
April 21, 2022.


Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.


CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)

For the period from 1st July 2021 to 31st March, 2022

	Amount in Taka	
	July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021
Cash Flows From Operating Activities:		
Received from revenue and others	6,400,545,446	5,399,077,175
Payment for operation, expenses & others	(5,866,919,698)	(4,800,095,561)
Miscellaneous income	782,705	2,418,834
Cash generated from operations	534,408,453	601,400,448
Cash payment for Income tax paid	(164,497,478)	(130,549,614)
Payment for financial charges	(31,330,593)	(28,247,654)
Net cash provided by operating activities	338,580,383	442,603,180
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(239,880,014)	(255,208,302)
Proceeds from sales of motor vehicles	-	1,213,365
Investment in associates (disposal)	60,000,000	-
Investment in subsidiary	-	3,500,160
Dividend Received/ IBBL-MPB	394,692	-
Received from bank deposits	115,930	761,849
Net cash used in investing activities	(179,369,392)	(249,732,929)
Cash Flows From Financing Activities:		
Payment of dividend	(123,540,169)	(117,026,036)
Long term finance received/(paid) from bank (Net)	(27,460,073)	130,756,446
Short term finance received/(paid) from bank (Net)	63,991,911	(165,452,562)
Non-Controlling Interest	17,500,000	-
Net cash used in financing activities	(69,508,331)	(151,722,152)
Increase/(decrease) in cash and cash equivalents	89,702,660	41,148,099
Cash and cash equivalents at the opening	281,235,883	199,913,735
Foreign exchange fluctuation gain/(loss) on FCAD ERQ Accounts	752,777	(10,509)
Cash and cash equivalents at the closing	371,691,320	241,051,325
NOCFPS (Note 32.A)	10.84	14.17


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
April 21, 2022.


Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.

STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 31st March, 2022

	Notes	Amount in Taka	
		31 March 2022	30 June 2021
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	04	2,714,001,200	2,470,531,996
Capital Work-In-Progress	05.1	2,270,571,456	2,166,874,444
Right of Use Assets	05.2	115,672,305	100,722,420
Investment in Marketable Securities (AFS)	06	89,930,973	9,566,112
Investment in Associates	07	13,826,665	5,179,715
Investment in Subsidiary	07.1	-	51,689,505
		223,999,800	136,499,800
Current Assets :			
Inventories	08	1,374,187,268	1,384,872,310
Trade and Other Receivables	09	876,214,527	781,760,330
Advances, Deposits & Prepayments	10	33,986,807	27,271,285
Cash & Cash Equivalents	11	210,411,892	342,082,195
		253,574,043	233,758,499
TOTAL ASSETS		<u>4,088,188,468</u>	<u>3,855,404,306</u>
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:			
Share Capital	12	2,430,416,871	2,159,859,988
Tax Holiday Reserve	13	312,436,270	312,436,270
Unrealised Gain on Marketable Securities (AFS)	14	4,392,110	4,392,110
Retained Earnings	15	168,300	145,087
		2,113,420,191	1,842,886,521
LIABILITIES:			
Non-Current Liabilities:			
Long Term Finance	16	607,089,720	540,577,920
Retirement Benefit Obligations	17.A	392,160,992	419,621,065
Lease Liability	17.B	564,970	94,029
Deferred Tax Liability	18	84,563,410	1,993,508
		129,800,347	118,869,318
Current Liabilities:			
Short Term Finance	20	1,050,681,877	1,154,966,398
Current Portion of Long Term Finance	21	444,905,388	377,502,715
Trade and Other Payable	22	65,448,342	67,532,217
Provision for Corporate Tax	23	407,432,076	430,861,133
		132,896,072	279,070,334
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		<u>4,088,188,468</u>	<u>3,855,404,306</u>
Net Assets Value (NAV) Per Share	31	77.79	69.13


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
April 21, 2022.


Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)

For the period from 1st July 2021 to 31st March, 2022

Amount in Taka

	Notes	July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021	January 01, 2022 to March 31, 2022	January 01, 2021 to March 31, 2021
REVENUE					
Cost of goods sold	24	6,407,260,968 (3,737,968,554)	5,399,371,735 (3,148,664,470)	1,879,425,116 (1,077,550,732)	1,791,871,586 (1,028,463,176)
GROSS PROFIT		2,669,292,414	2,250,707,265	801,874,384	763,408,410
OPERATING EXPENSES		(2,049,530,907)	(1,720,865,121)	(668,370,069)	(626,405,804)
Administrative expenses	25	(149,959,828)	(128,486,316)	(44,839,868)	(47,960,598)
Selling & Distribution expenses	26	(1,899,571,079)	(1,592,378,805)	(623,530,201)	(578,445,206)
OPERATING PROFIT		619,761,507	529,842,144	133,504,315	137,002,606
Financial charges	34	(35,125,390)	(29,176,312)	(11,030,656)	(10,224,336)
Other income		17,125,843	7,649,737	1,768,397	1,942,926
Net profit from operation		601,761,960	508,315,568	124,242,056	128,721,195
Workers' P.P. fund & welfare fund	27	(28,655,331)	(24,205,503)	(5,826,792)	(6,129,580)
PROFIT BEFORE TAX		573,106,629	484,110,065	118,415,264	122,591,615
Income tax expenses:					
Current Tax	28	(155,727,912)	(135,138,615)	(28,871,013)	(35,608,344)
NET PROFIT AFTER TAX		417,378,717	348,971,450	89,544,251	86,983,271
Other Comprehensive Income:					
Change in fair value of marketable securities	29	25,792	442,395	(452,783)	69,800
Deferred tax		(2,579)	(44,240)	45,278	(6,980)
Total other comprehensive income for the period (net of tax)		23,213	398,156	(407,504)	62,820
Total Comprehensive Income for the period		417,401,930	349,369,605	89,136,747	87,046,091
Earnings Per Share (EPS)	30	13.36	11.17	2.85	2.79
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
April 21, 2022.


Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.

STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the period from 1st July 2021 to 31st March, 2022

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (unrealized)	Retained Earnings	Total
Balance as at 1st July, 2020	312,436,270	4,392,110	(212,402)	1,465,681,162	1,782,297,140
Statement of profit or loss and other Comprehensive Income/(Loss)-2020-21	-	-	357,489	497,493,323	497,850,812
Dividend for the period 30 June, 2020 (Cash - 38.50%)	-	-	-	(120,287,964)	(120,287,964)
Balance as at 30th June, 2021	312,436,270	4,392,110	145,087	1,842,886,521	2,159,859,988
Statement of profit or loss and other Comprehensive Income for period ended 31st March, 2022	-	-	23,213	417,378,717	417,401,930
Dividend for the year 30 June, 2021 (Cash- 47%)	-	-	-	(146,845,047)	(146,845,047)
Balance as at 31st March, 2022	312,436,270	4,392,110	168,300	2,113,420,191	2,430,416,871


STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the period from 1st July 2020 to 31st March, 2021

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (unrealized)	Retained Earnings	Total
Balance as at 1st July, 2019	312,436,270	4,392,110	(126,137)	1,161,594,152	1,478,296,395
Statement of profit or loss and other Comprehensive Income/(Loss)-2019-20	-	-	(86,265)	397,817,891	397,731,626
Dividend for the period 30 June, 2019 (Cash - 30%)	-	-	-	(93,730,881)	(93,730,881)
Balance as at 30th June, 2020	312,436,270	4,392,110	(212,402)	1,465,681,162	1,782,297,140
Statement of profit or loss and other Comprehensive Income for period ended 31st March, 2021	-	-	398,156	348,971,450	349,369,605
Dividend for the year 30 June, 2020 (Cash- 38.50%)	-	-	-	(120,287,964)	(120,287,964)
Balance as at 31st March, 2021	312,436,270	4,392,110	185,754	1,694,364,648	2,011,378,781


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .


Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.

STATEMENT OF CASH FLOWS (Unaudited)

For the period from 1st July 2021 to 31st March, 2022

	Amount in Taka	
	July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021
Cash Flows From Operating Activities:		
Received from revenue and others	6,400,545,446	5,399,077,175
Payment for operation, expenses & others	(5,863,418,399)	(4,792,286,227)
Miscellaneous income	782,705	1,854,909
Cash generated from operations	537,909,752	608,645,856
Cash payment for Income tax paid	(164,497,478)	(130,493,221)
Payment for financial charges	(31,330,593)	(28,247,654)
Net cash provided by operating activities	342,081,682	449,904,982
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(208,933,040)	(240,502,048)
Proceeds from sales of motor vehicles	-	1,213,365
Investment in associates (disposal)	60,000,000	-
Investment in subsidiary	(87,500,000)	(67,630,280)
Dividend Received/ IBBL-MPB	394,692	-
Received from bank deposits	27,764	761,849
Net cash used in investing activities	(236,010,584)	(306,157,114)
Cash Flows From Financing Activities:		
Payment of dividend	(123,540,169)	(117,026,036)
Long term finance received/(paid) from bank (Net)	(27,460,073)	130,756,446
Short term finance received/(paid) from bank (Net)	63,991,911	(165,452,562)
Net cash used in financing activities	(87,008,331)	(151,722,152)
Increase/(decrease) in cash and cash equivalents	19,062,767	(7,974,285)
Cash and cash equivalents at the opening	233,758,499	199,901,663
Foreign exchange fluctuation gain/(loss) on FCAD ERQ Accounts	752,777	(10,509)
Cash and cash equivalents at the closing	<u>253,574,043</u>	<u>191,916,869</u>
NOCFPS (Note 32)	10.95	14.40


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
April 21, 2022.


Managing Director


Chairman

The IBN SINA Pharmaceutical Industry Ltd.
Selected Notes to the Financial Statements (Unaudited)
For the period from 1st July 2021 to 31st March, 2022

Selected Explanatory Notes:

01. (a) Basis of Preparation of Financial Statements:

These Third Quarter Financial Statements have been prepared in line with the accounting policies and methods of computations of the periodic Financial Statements prepared and published for the year ended 30th June 2021. These interim Financial Statements includes only selected explanatory notes as deemed appropriate for understanding of these unaudited Financial Statements.

01. (b) Reporting:

This Third Quarter financial report has been prepared based on International Accounting Standard (IAS) 34 "Interim Financial Reporting".

01. (c) Earnings Per Share (EPS):

Earnings Per Share has been calculated based on number of shares outstanding for the period ended March 31, 2022 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2021 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

01. (d) Subsequent events:

No Material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

01. (e) Increase in Earnings Per Share (EPS):

As a result of increment in sales revenue and profit , EPS has been increased during current period over last reporting period.

01. (f) Decrease in Net Operating Cash Flow Per Share (NOCFPS):

Net Operating Cash Flow Per Share (NOCFPS) decreased during current period over last reporting period due to increase in payment for cost & expenses & others.

01. (g) Income Tax:

Payment of income tax increased due to increase in revenue and net profit. Advance income tax and tax payable decrease due to completion of income tax assessment.

01. (h) Payment for property plant and equipment:

Payment for purchases of property plant and equipment decreased due to less addition of property plant and equipment during this reporting period.

01. (i) Other income:

Other income increased during the period due to increase in revenue from toll production charge, gain on disposal of share of IBN SINA Consumer Product Ltd. and payment received from Provident Fund (PF) forfeiture returned during this period from The IBN SINA Pharmaceuticals Industry Ltd. Employees Provident Fund.

01. (j) Payment of dividend increased due to declaration of higher dividend on last year's income during the reporting period.

01.(k) Finance charge:

Finance charge during the reporting period increased due to increase of long term loan.

01.(l) Increase in Revenue:

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

02. Statement of compliance:

The Financial Statements have been prepared in accordance with International Financial Reporting Standards (IFRSs) and International Accounting Standards (IASs), the Companies Act, 1994, Securities and Exchange Rules, 1987 and other relevant laws as applicable.

03. Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.

04. PROPERTY, PLANT AND EQUIPMENT:

31 March 2022	30 June 2021
---------------	--------------

Cost :

Opening balance	3,221,268,535	2,872,974,134
Addition during the period	251,037,273	352,617,686
Disposal/Adjustment during the period	-	(4,323,285)
Closing balance	3,472,305,808	3,221,268,535

Accumulated Depreciation:

Opening balance	1,054,394,091	869,527,947
Charged during the period	147,340,261	188,972,041
Disposal/Adjustment during the period	-	(4,105,898)
Closing balance	1,201,734,352	1,054,394,090

Closing balance of Written Down Value (WDV)	2,270,571,456	2,166,874,444
--	----------------------	----------------------

The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:

The IBN SINA Pharmaceutical Industry Ltd.	2,270,571,456	2,166,874,444
The IBN SINA API Industry Ltd.	50,302,229	42,859,803
	2,320,873,685	2,209,734,247

05.1 CAPITAL WORK-IN-PROGRESS:**A) Construction work-in-progress (Building)**

Opening balance	72,549,664	42,997,913
Add: Addition during the period	57,054,118	29,551,751
Less: Transferred to property, plant and equipment	(72,549,664)	-
	57,054,118	72,549,664

B) Machinery in transit and installation

	58,618,187	28,172,756
	115,672,305	100,722,420

i) Some new construction is under process to increase the overall production capacity of The IBN SINA Pharmaceutical Industry Ltd. The amount in machinery in transit represents the amount for opening the LC for the procurement of Factory machineries for newly constructed factory building and increasing production capacity of existing factory which are not received yet by the company.

ii) Building construction in the factory premises has been completed during this period and hence the construction and associated cost is transferred from capital work in progress to building under property, plant and equipment.

05.1A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:

Opening balance	83,236,939	48,757,241
Addition during the period	80,360,146	34,479,698
Less: Transferred to property, plant and equipment	(72,549,664)	-
Closing balance	91,047,421	83,236,939
Machinery in transit and installation	58,618,187	28,172,756
	149,665,608	111,409,695

	Amount in Taka	
	31 March 2022	30 June 2021
05.2 RIGHT OF USE ASSETS:		
Cost:		
Opening balance	62,623,935	62,623,935
Addition during the period	95,813,860	-
Closing balance	158,437,795	62,623,935
Accumulated Depreciation:		
Opening balance	(53,057,823)	(26,436,339)
Charged during the period	(15,448,999)	(26,621,484)
Closing balance	(68,506,822)	(53,057,823)
Closing balance of Written Down Value (WDV)	89,930,973	9,566,112

Right of use of Asset increase due to contract renewal of Head Office.

06. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE):

Exim Bank Limited	1,325,000	523,160
First Security Islami Bank Ltd.	6,380,000	-
Shahjalal Islami Bank Ltd.	1,332,000	-
Islami Bank Bangladesh Ltd. (IBBL) in MPB	4,789,665	4,656,555
	13,826,665	5,179,715

The above investment in marketable securities are designated as available for sale (AFS) by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. The shares of Exim Bank Limited, First Security Islami Bank Ltd., Shahjalal Islami Bank Ltd. and IBBL-MPB are listed in Dhaka Stock exchange and Chittagong Stock exchange. The whole investment in shares of both the companies are in DSE only. The market value of each share of IBBL-MPB was at Tk. 1,043.50, Exim Bank Limited was Tk. 12.50, First Security Islami Bank Ltd. was Tk. 11.60 and Shahjalal Islami Bank Ltd. was Tk. 22.20.

07. INVESTMENT IN ASSOCIATES:

Investment in shares

Opening balance	60,000,000	60,000,000
Less: Disposal (Received from IBN SINA Consumer Product Ltd.)	(60,000,000)	-
	-	60,000,000
Post acquisition cumulative profit/(loss)		
Opening retained earnings balance of loss	(8,310,495)	(6,383,565)
Add: Gain on disposal	8,310,495	(1,926,929)
	-	(8,310,495)
	-	51,689,505

Investment in associate has been valued at cost. No loan or advance has been given to associate company.

07.1 INVESTMENT IN SUBSIDIARY :

The IBN SINA API Industry Ltd.	154,999,800	99,999,800
The IBN SINA Natural Medicine Ltd.	30,000,000	30,000,000
IBN SINA Polymer Industry Ltd.	39,000,000	6,500,000
	223,999,800	136,499,800

i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk.5.50 crore have been paid as a part of share capital.

ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.

iii) IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company.

Amount in Taka

08. INVENTORIES:

	31 March 2022	30 June 2021
Raw materials	230,065,067	203,135,206
Packing materials	147,477,898	112,592,756
Work-in-process	103,938,736	87,572,144
Finished goods	225,470,364	222,215,206
Physicians' samples	3,642,179	3,638,179
Pad & literature	2,977,626	2,907,461
Spares & stores	192,565	183,882
Indirect materials	282,368	273,393
Printing & stationery	284,162	274,563
Laboratory chemicals	198,427	189,537
Material in transit	161,685,135	148,778,003
	876,214,527	781,760,330

08.A CONSOLIDATED INVENTORIES:

Raw materials	230,403,767	203,538,531
Packing materials	147,477,898	112,592,756
Work-in-process	103,938,736	87,572,144
Finished goods	225,470,364	222,215,206
Physicians' samples	3,642,179	3,638,179
Pad & literature	2,977,626	2,907,461
Spares & stores	192,565	183,882
Indirect materials	282,368	273,393
Printing & stationery	284,162	274,563
Laboratory chemicals	198,427	189,537
Material in transit	161,685,135	148,778,003
	876,553,227	782,163,655

- i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, milligram and ton as such quantity can not be inserted.
- ii) There is no damage goods or slow moving item in the inventory list.
- iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.
- iv) Inventory for Raw materials , Packing materials, Work In Process, Finished goods and pad & literature increased during the period for ensuring smooth supply of products.
- v) All of the inventories have been valued at cost and net realizable value of the inventories are higher than their cost.

09. TRADE AND OTHER RECEIVABLES:

Trade receivable	24,759,881	23,609,681
Receivable from provident fund (PF)	-	613,125
Dividend receivable	-	394,692
Other receivable-toll charge	9,226,926	2,653,787
	33,986,807	27,271,285

- i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.
- ii) Other receivable increased during the period as last month toll charge bill remain receivable.

10. ADVANCES, DEPOSITS & PREPAYMENTS :

a. Advances against

Salary	3,787,810	3,663,147
Expenses/works/others	8,806,218	7,106,346
Depot rent	9,381,199	11,150,455
Motor cycles-to employees	8,602,277	7,606,797
Others	579,814	712,908
	31,157,318	30,239,653

		Amount in Taka	
		31 March 2022	30 June 2021
b. Income tax			
Opening balance		290,522,128	133,670,451
Addition		164,497,478	186,565,279
Adjusted during the period		(290,973,724)	(29,713,602)
		164,045,882	290,522,128
c. Deposits			
Security money		15,125,844	21,320,410
d. Pre payments			
Value Added Tax		82,848	4
		210,411,892	342,082,195
10.1 MATURITY ANALYSIS:			
Realizable/adjustable within one year.		198,750,892	320,421,195
Realizable/adjustable after one year.		11,661,000	21,661,000
		210,411,892	342,082,195
10.A CONSOLIDATED ADVANCES, DEPOSITS & PREPAYMENTS :			
a. Advances against			
Salary		3,787,810	3,663,147
Expenses/works/others		9,463,781	7,106,346
Depot rent		9,381,199	11,150,455
Motor cycles-to employees		8,602,277	7,606,797
API Industrial Park Services Limited		25,000,000	25,000,000
Others		579,814	712,908
		56,814,881	55,239,653
b. Income tax			
Opening balance		290,597,362	133,671,271
Addition		164,506,294	186,639,692
Adjusted during the period		(290,973,724)	(29,713,602)
		164,129,932	290,597,362
c. Deposits			
Security money		15,125,844	21,320,410
d. Pre payments			
Value Added Tax		82,848	4
		236,153,505	367,157,429
i) The company did not give any advance, deposit and prepayment to the director's of the company, subsidiary, associates and other connected party and employees advances are realised in normal course of business.			
ii) Advance against works increase during this period to meet up business needs.			
iii) Security money decrease during this period as security money return by various parties.			
11. CASH & CASH EQUIVALENTS:			
a. Cash in hand		4,716,725	5,673,476
b. Cash at bank		245,183,318	219,815,023
c. Imprest cash		3,674,000	8,270,000
		253,574,043	233,758,499
11.A CONSOLIDATED CASH & CASH EQUIVALENTS:			
a. Cash in hand		4,716,725	5,673,476
b. Cash at bank		363,300,595	267,292,407
c. Imprest cash		3,674,000	8,270,000
		371,691,320	281,235,883

		Amount in Taka	
		31 March 2022	30 June 2021
12. SHARE CAPITAL:			
Authorized:			
Authorized:			
50,000,000 Ordinary Shares of Tk. 10 each		500,000,000	500,000,000
Issued, Subscribed & Paid-Up :			
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash		312,436,270	312,436,270
The Shareholdings consist of :			
Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,839,112	44.29%
Institution (I.C.B)	208	7,428,874	23.78%
General Public	12,030	9,975,641	31.93%
	12,239	31,243,627	100.00%
The distribution schedule showing the number of share holders and their share holdings as on 31.03.2022 are as follows:			
Range of Holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	9,731	1,818,306	5.97%
500 to 5,000 shares	1,997	3,010,194	11.36%
5,001 to 10,000 shares	167	1,310,103	4.69%
10,001 to 20,000 shares	80	1,322,917	4.73%
20,001 to 30,000 shares	25	704,057	2.98%
30,001 to 40,000 shares	7	408,231	2.00%
40,001 to 50,000 shares	9	618,367	1.83%
Above 50,000 shares	14	22,051,452	66.43%
	12,030	31,243,627	100.00%
i) The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quoted at Tk.298.10 in the Dhaka Stock Exchange Limited on 31.03.2022 and at Tk.285.30 in the Chittagong Stock Exchange Limited on 27.03.2022 respectively.			
ii) The Directors and Share Holders who hold 10% (Ten percent) or more shares of the company have not availed any loan or credit facility by lien or pledge of their shares to the lender at the time borrowing. No margin loan from the stock brokers or portfolio manager was taken by the said directors and share holders.			
13. TAX HOLIDAY RESERVE:		4,392,110	4,392,110
This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.			
14. UNREALISED GAIN ON MARKETABLE SECURITIES :			
Closing market value of marketable securities		13,826,665	5,179,715
Less: Cost of marketable securities		13,639,665	5,018,507
Unrealized gain before adjustment of deferred tax		187,000	161,208
Less: Deferred tax on unrealized gain (loss)		18,700	16,121
Net unrealized gain/(loss) on marketable securities		168,300	145,087
15. RETAINED EARNINGS:			
Opening Balance		1,842,886,521	1,465,681,162
Dividend paid		(146,845,047)	(120,287,964)
Add : Net profit during the period		417,378,717	497,493,323
		2,113,420,191	1,842,886,521
15A. CONSOLIDATED RETAINED EARNINGS:			
Opening Balance		1,829,226,006	1,460,390,581
Dividend paid		(146,845,047)	(120,287,964)
Add: Net profit during the period		414,498,701	489,123,389
		2,096,879,661	1,829,226,006
15B. NON CONTROLLING INTEREST:			
The IBN SINA API Industry Limited		200	200
The IBN SINA Natural Medicine Ltd.		3,000	3,000
IBN SINA Polymer Industry Ltd. (Paid by The IBN SINA Trust)		21,000,000	3,500,000
Add: Share of Profit/(Loss)		(221,700)	(151,618)
		20,781,500	3,351,582

Amount in Taka

16. LONG TERM FINANCE :

i) From Al-Arafah Islami Bank Limited Secured
(Under Hire Purchase Shirkatul Melk-HPSM)
Current maturity transferred to current liability

i) From Al-Arafah Islami Bank Limited Secured
(Under Hire Purchase Shirkatul Melk)

Note -21

LONG TERM FINANCE - net off current maturity

	31 March 2022	30 June 2021
	456,282,448	484,783,270
	(64,121,456)	(65,162,205)
	392,160,992	419,621,065

i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial position @ 9% of profit.

ii) The loan was taken from Al-Arafah Islami Bank Limited against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import capital machinery and motor vehicle under Hire Purchase Shirkatul Melk.

iii) HPSM is repayable in 84 monthly equal installment.

iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.

v) Information regarding loan fall due after five years.

Loan fall due from 2 to 5 years

Loan fall due from 6 to more years

	304,188,299	323,188,847
	87,972,694	96,432,218
	392,160,992	419,621,065

17. A RETIREMENT BENEFIT OBLIGATIONS:

Opening Balance

Provision during the period

Less: Paid during the period

	94,029	78,797
	93,587,748	86,531,199
	(93,116,806)	(86,515,967)
	564,970	94,029

17. B LEASE LIABILITY:

Opening Balance

Addition during the period

Finance charge

Paid during the period

Closing balance

Less : Transferred to current maturity

	4,363,520	25,369,109.00
	84,152,860	-
	3,794,797	1,238,211
	(6,420,881)	(22,243,800)
	85,890,296	4,363,520
	(1,326,886)	(2,370,012)
	84,563,410	1,993,508

i) The company has lease against its Head Office and its training center located at Mohammadpur, Dhaka.

ii) Lease period is upto 31.10.2026.

iii) Monthly rental payment is Tk.1,851,270.

iv) Advance amount paid Tk. 11,661,000.

18. DEFERRED TAX LIABILITY/(ASSETS):

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax (expense)/income have been disclosed in note 19. The components of deferred tax assets and liabilities are given below: -

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability/(assets)
Property, plant and equipment	2,270,571,456	1,697,239,842	573,331,614	22.50%	128,999,613
Gratuity	93,681,778	93,116,806	(564,972)	22.50%	(127,119)
Lease	4,040,677	-	4,040,677	22.50%	909,152
Unrealized gain on marketable securities	187,000	-	187,000	10.00%	18,700
For the period 31st March 2022	2,368,480,911	1,790,356,648	576,994,319		129,800,347
Property, plant and equipment	2,166,874,444	1,637,826,077	529,048,367	22.50%	119,035,883
Gratuity	86,609,997	86,515,967	(94,030)	22.50%	(21,157)
Lease	5,202,592	5,920,500	(717,908)	22.50%	(161,529)
Unrealized gain on marketable securities	161,208	-	161,208	10.00%	16,121
For the year 2020-2021	2,258,848,241	1,730,262,544	528,397,637		118,869,318

		Amount in Taka	
		31 March 2022	30 June 2021
19. DEFERRED TAX (EXPENSES)/INCOME :			
	Closing balance of deferred tax liability	129,800,347	118,869,317
	Opening balance of deferred tax liability	118,869,318	108,988,015
	Total deferred tax expenses	10,931,029	9,881,303
	Less/Add: Deferred tax expenses related to other comprehensive income	(2,579)	(44,240)
		10,928,450	9,837,063
20. SHORT TERM FINANCE :			
	A. From Al-Arafah Islami Bank Limited - Secured (Under Composite facilities LC(MPI/TR))	444,905,388	377,502,715
		444,905,388	377,502,715
	i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of Statement of Financial Position @ 9% of profit and 0.25% commission per quarter to be paid.		
	ii) The loan was taken from Al-Arafah Islami Bank Limited against mortgage of 803 decimal land and 63, 811 square feet factory building located at Shafipur, Gazipur to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite investment facilities LC/MPI/MIB/ TR/UPAS/ Baimuajjal agreement.		
	iii) Short term loan is repayable with in twelve months.		
	iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.		
21. CURRENT PORTION OF LONG TERM FINANCE:			
	i) From Al-Arafah Islami Bank Limited-Secured (Under Hire Purchase Shirkatul Melk)	64,121,456	65,162,205
	ii) Current portion of lease	1,326,886	2,370,012
		65,448,342	67,532,217
	The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank Limited and lease liability which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.		
22. TRADE AND OTHER PAYABLE :			
	Payable to suppliers	225,724,875	231,649,393
	Accrued expenses	103,109,333	101,855,213
	Security money received from employees and others	8,562,855	8,438,345
	Other Finance	70,035,013	88,918,181
		407,432,076	430,861,133
22.A CONSOLIDATED TRADE AND OTHER PAYABLE :			
	Payable to suppliers	225,724,875	231,649,393
	Accrued expenses	103,109,333	101,941,463
	Security money received from employees and others	8,562,855	8,438,345
	Others Finance	70,035,013	88,918,181
		407,432,076	430,947,383
22.1 OTHER FINANCE :			
	This consists of :		
	Unclaimed dividend	41,379,682	53,184,517
	Workers' profit participation fund & welfare fund	28,655,331	28,607,860
		70,035,013	81,792,376
22.1.1 UNCLAIMED DIVIDEND :			
	Opening	53,184,516	64,404,243
	Addition	146,845,047	120,287,964
	Paid to share holders	(123,540,169)	(131,507,691)
	Paid to Capital Market Stabilisation Fund	(35,109,712)	-
		41,379,682	53,184,516

Amount in Taka

22.1.2 UNCLAIMED DIVIDEND :

Year-wise break-up of the above is as follows :

Previous years

2017-18

2018-19

2019-20

2020-21

	31 March 2022	30 June 2021
	-	30,599,507
	-	5,594,304
	4,419,868	7,105,354
	8,045,763	9,885,352
	28,914,052	-
	41,379,682	53,184,517

23. INCOME TAX LIABILITY:

Opening balance

Tax payable/ Prior year tax assessment adjustment

Current tax expense

Adjusted during the year/period

	279,070,334	103,372,479
	4,200,000	48,311,580
	140,599,462	157,099,877
	423,869,796	308,783,936
	(290,973,724)	(29,713,602)
	132,896,072	279,070,334

23.A CONSOLIDATED INCOME TAX LIABILITY:

Opening balance

Tax payable/ Prior year tax assessment adjustment

Current tax expense

Adjusted during the year/period

	279,296,238	103,375,142
	4,200,000	48,311,580
	140,625,912	157,323,117
	424,122,149	309,009,840
	(290,973,724)	(29,713,602)
	133,148,425	279,296,238

i) Income tax liability decreased during this period as last two years income tax assessment (AY 2020-2021 and 2021-2022) adjustment.

Amount in Taka

24. COST OF GOODS SOLD :

	July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021
Materials	2,998,521,187	2,510,311,522
Factory Overhead	622,053,017	527,029,963
Depreciation	117,394,350	111,322,985
	3,737,968,554	3,148,664,470

i) Cost of materials, expenses incurred for factory overhead and depreciation expense during the reporting period increased due to increase in sales, increase in production and addition of fixed assets respectively .

25. ADMINISTRATIVE EXPENSES :

Salary, Wages & Allowances	71,604,610	59,554,370
Repairs & Maintenance	7,631,922	6,054,844
Travelling & Conveyance	4,373,638	3,225,389
AGM, Fees and Others	1,886,615	1,230,200
Depreciation	18,835,351	19,287,491
Other Expenses	45,627,692	39,134,022
	149,959,828	128,486,316

25.A CONSOLIDATED ADMINISTRATIVE EXPENSES :

Salary, Wages & Allowances	73,832,149	61,175,093
Repairs & Maintenance	7,631,922	6,054,844
Travelling & Conveyance	4,373,638	3,225,389
AGM, Fees and Others	1,886,615	1,238,364
Research & Development	64,625	5,374,324
Preliminary Expenses	-	780,416
Depreciation	19,033,870	19,486,011
Other Expenses	46,148,823	39,174,367
	152,971,642	136,508,808

- i) Salary, wages & allowance increased due to increase in manpower and gratuity payment.
ii) Repairs & Maintenance expense during the reporting period increased due to renovation of assets.
iii) Travelling & conveyance increased during the period due to increase in bus fare and related cost.
iv) AGM expenses increased due to increase in printing, postal charge and other related expenses.
v) Research & Development expense decreased during the reporting period due to meetup current business need.

26. SELLING & DISTRIBUTION EXPENSES :

Salary, Wages & Allowances	1,059,725,678	894,841,236
Travelling & Conveyance	4,170,620	3,965,888
Market Survey & Research and Product development	5,126,857	4,850,691
Field personnel expenses	249,960,937	182,073,731
Sample, Literature & Promotional Expenses	85,748,560	80,745,962
Delivery Expenses	154,857,753	132,002,118
Depreciation	26,559,559	27,767,171
Other Expenses	313,421,116	266,132,009
	1,899,571,079	1,592,378,805

- i) Salary, wages & allowance increase due to increase in manpower and gratuity payment.
ii) Field personnel expense increase due to increase of field personnel movement in order to increase sales.
iii) Delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.

		Amount in Taka	
		July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021
27.	WORKERS' P.P FUND & WELFARE FUND :	28,655,331	24,205,503
28.	INCOME TAX EXPENSES:		
	Current Tax	144,799,462	121,408,620
	Deferred Tax income/(expense)	10,928,450	13,729,995
		155,727,912	135,138,615
	Reconciliation of Effective Tax Rate		
	Types of income	Income	Effective Tax Rate
	Capital Gain	-	20.00%
	Business Income	573,106,629	22.50%
		573,106,629	22.50%
	Non Deductible Expenses		4.67%
			27.17%
			155,727,912
28.A	CONSOLIDATED INCOME TAX EXPENSES:		
	Current Tax	144,825,912	121,591,896
	Deferred Tax income/(expense)	10,928,450	13,729,995
		155,754,362	135,321,891
29.	CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES :		
	Closing value of marketable securities	187,000	206,393
	Opening value of marketable securities	161,208	(236,002)
		25,792	442,395
30.	EARNINGS PER SHARE (EPS) :		
	Basic earnings per share has been calculated as follows :		
	Earnings attributable to the Ordinary Shareholders (Net profit after tax)	417,378,717	348,971,450
	Divided by number of Ordinary Shares outstanding during the year/period	31,243,627	31,243,627
		13.36	11.17
30.A	CONSOLIDATED EARNINGS PER SHARE (EPS) :		
	Basic earnings per share has been calculated as follows :		
	Earnings attributable to the ordinary shareholders (Net profit after tax)	414,428,619	341,329,607
	Divided by number of ordinary shares outstanding during the year/period	31,243,627	31,243,627
		13.26	10.92
31.	Net Assets Value Per Share (NAV):		
	Net Assets Value	2,430,416,871	2,159,859,988
	Divided by number of ordinary shares outstanding during the period	31,243,627	31,243,627
		77.79	69.13
31.A	Consolidated Net Assets Value Per Share (NAV):		
	Net Assets Value	2,413,876,341	2,146,199,473
	Divided by number of ordinary shares outstanding during the period	31,243,627	31,243,627
		77.26	68.69

Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earning.

Amount in Taka

	July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021
32. Net Operating Cash Flow Per Share (NOCFPS):		
Net cash provided by operating activities	342,081,682	449,904,982
Divided by number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
	10.95	14.40
32.A Consolidated Net Operating Cash Flow Per Share (NOCFPS):		
Net cash provided by operating activities	338,580,383	442,603,180
Divided by number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
	10.84	14.17
33. Reconciliation of net profit with cash flows from operating activities:		
Profit Before Tax (PBT)	573,106,629	484,110,065
Adjustment		
Depreciation	162,789,260	158,377,647
Deferred Tax	10,931,029	13,729,995
Unrealized foreign exchange loss	(752,777)	10,509
Gain on sale of Motor Vehicles	-	1,213,365
Dividend received	394,692	-
Interest Income	(27,764)	(761,849)
Other Income	613,125	-
Change in operating assets		
Increase in inventory	(94,454,196)	(111,006,234)
Increase in accounts receivables	(6,715,522)	(294,560)
Decrease in advances, deposits and prepayments	5,276,902	4,397,087
Increase/(decrease) in trade and other payable	(113,722,567)	58,851,865
Increase/(decrease) in retirement benefit obligation	470,942	17,967
Finance charge	(31,330,593)	(28,247,654)
Tax paid during the period	(164,497,478)	(130,493,221)
	342,081,682	449,904,982
33.A Consolidated Reconciliation of net profit with cash flows from operating activities:		
Profit Before Tax (PBT)	570,182,981	476,651,498
Adjustment		
Depreciation	162,987,779	158,576,167
Deferred Tax	10,931,029	13,729,995
Unrealized foreign exchange loss	(752,777)	10,509
Gain on sale of Motor Vehicles	-	1,213,365
Dividend received	394,692	-
Interest Income	(27,764)	(761,849)
Other Income	613,125	-
Change in operating assets		
Increase in inventory	(94,389,571)	(110,962,847)
Increase in accounts receivables	(6,715,522)	(294,560)
Decrease in advances, deposits and prepayments	4,536,494	4,397,087
Increase/(decrease) in trade and other payable	(113,814,139)	58,766,723
Increase/(decrease) in retirement benefit obligation	470,942	17,967
Finance charge	(31,330,593)	(28,247,654)
Tax paid during the period	(164,506,294)	(130,493,221)
	338,580,383	442,603,180

Amount in Taka

July 01, 2021 to March 31, 2022	July 01, 2020 to March 31, 2021
------------------------------------	------------------------------------

34. Finance Charge:

Finance charge for long term finance

31,330,593

28,247,654

Finance charge for lease

3,794,797

928,658

35,125,390**29,176,312**

35. RELATED PARTY TRANSACTIONS:

During the year, the company carried out transactions with related parties in the normal course of business and on an arm's length transaction basis. The name of related parties, relationship, types of transaction and their total value have been set out in accordance with the provisions of IAS 24 "Related Party Disclosures". Transaction with related parties are executed on the same terms as those of other customers of similar credentials and do not involve more than a normal risk.


Name of party	Relations hip	Nature of transaction	Transaction		2021-2022	2020-2021
			Dr.	Cr.	Receivable/(Payable)	
1. The IBN SINA Trust	Sponsor shareholder	Dividend payment	47,447,326	-	-	-
2. IBN SINA Consumer Products Ltd.	Associate	Disposal of share Capital	-	60,000,000	-	53,616,435
3. The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital	55,000,000		154,999,800	99,999,800
4. The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Capital	-		30,000,000	30,000,000.00
5. IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Acquisition of share Capital	32,500,000		39,000,000	6,500,000.00


35.01 Transaction with key management personnel and their compensation

Particulars	2021-2022	2020-2021
Short term employee benefits	10,400,000	8,300,000
Post-employment benefits	-	-
Other long term benefits	-	-

Key management personnel compensation includes benefits for employees of the rank of director and above. No remuneration is given to the board of director's apart from attendance fees in connection with board and subcommittee meeting during the year 2021-202 attendance fees in connection with board and sub board committee meeting are Tk.1,182,000 (2020-2021 Tk. 1,101,800).


Chief Financial Officer


Company Secretary


Director, Finance

Dated, Dhaka .
April 21, 2022.


Managing Director


Chairman